Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Klerk CPW"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vera de Jonge, A., Duetz, C, Bruins, WSC, van Werkhoven, Erik, Nijland, M., van der Poel, Marjolein W. M., de Heer, K, Klerk, CPW, Sandberg, Yorick, Fijnheer, Rob, Mutsaers, Pim G.N.J., Issa, DE, Lara H Bohmer, van Kampen, Roel J.W., Visser, O, de Jong, D, Zijlstra-Baalbergen, JM, Mutis, T, Chamuleau, MED
Publikováno v:
Blood. American Society of Hematology
Vera de Jonge, A, Duetz, C, Bruins, WSC, van Werkhoven, E, Nijland, M, van der Poel, M W M, de Heer, K, Klerk, CPW, Sandberg, Y, Fijnheer, R, Mutsaers, P G N J, Issa, DE, Lara H Bohmer, van Kampen, R J W, Visser, O, de Jong, D, Zijlstra-Baalbergen, JM, Mutis, T & Chamuleau, MED 202, ' Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion ', Blood .
Vera de Jonge, A, Duetz, C, Bruins, WSC, van Werkhoven, E, Nijland, M, van der Poel, M W M, de Heer, K, Klerk, CPW, Sandberg, Y, Fijnheer, R, Mutsaers, P G N J, Issa, DE, Lara H Bohmer, van Kampen, R J W, Visser, O, de Jong, D, Zijlstra-Baalbergen, JM, Mutis, T & Chamuleau, MED 202, ' Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion ', Blood .
Introduction Treatment of patients with high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) with intensified immune-chemotherapy DA-EPOCH-R results in a 48-month event-free survival of 71.0% [Dunleavy, Lancet Haematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0991eaec201425d3c465a738feb028
https://research.vumc.nl/en/publications/e9fcd0d7-06d9-43bd-b7cf-1caa86c2eb2c
https://research.vumc.nl/en/publications/e9fcd0d7-06d9-43bd-b7cf-1caa86c2eb2c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
de Jonge AV; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Duetz C; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Bruins WSC; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Korst CLBM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Rentenaar R; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Cosovic M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Eken M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Twickler I; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Nijland M; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., van der Poel MWM; Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., de Heer K; Department of Internal Medicine, Flevoziekenhuis, Almere, The Netherlands., Klerk CPW; Department of Internal Medicine, Dijklanderziekenhuis, Hoorn, The Netherlands., Strobbe L; Department of Internal Medicine, Gelreziekenhuizen, Zutphen, The Netherlands., Oosterveld M; Department of Internal Medicine, CWZ, Nijmegen, The Netherlands., Boersma R; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands., Koene HR; Department of Hematology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands., Roemer MGM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., van Werkhoven E; HOVON Foundation, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Chamuleau MED; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Mutis T; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
Publikováno v:
Blood advances [Blood Adv] 2024 Mar 12; Vol. 8 (5), pp. 1094-1104.
Autor:
De Jong CN; Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands., Saes L; Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands., Klerk CPW; Department of Hematology and Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands., Van der Klift M; Department of Hematology, Amphia Hospital, Breda, the Netherlands., Cornelissen JJ; Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands., Broers AEC; Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.
Publikováno v:
PloS one [PLoS One] 2017 Oct 26; Vol. 12 (10), pp. e0187184. Date of Electronic Publication: 2017 Oct 26 (Print Publication: 2017).
Autor:
Libourel EJ; Department of Hematology/Oncology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands.; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Klerk CPW; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands; and., van Norden Y; Clinical Trial Center-HOVON Data Center, Erasmus MC, Rotterdam, The Netherlands., de Maat MPM; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Kruip MJ; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Sonneveld P; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Löwenberg B; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Leebeek FWG; Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands.
Publikováno v:
Blood [Blood] 2016 Oct 06; Vol. 128 (14), pp. 1854-1861. Date of Electronic Publication: 2016 Jun 28.